<div id="readability-page-1"><div><ul> <li>Wondering whether Veeva Systems at around US$168.25 is a bargain or a stock to be cautious with? This article breaks down what the current price might really imply about value.</li> <li>The stock has recently shown a 7.9% gain over the past week, but this sits against a 2.5% decline over the past month, a 23.3% fall year to date, and a 29.8% decline over the last year.</li> <li>Recent coverage has highlighted Veeva Systems in the context of broader market interest in healthcare software and data platforms, with investors paying close attention to how such companies are positioned within the sector. At the same time, there has been ongoing discussion about valuations across higher growth software stocks generally, which provides important context for these recent moves.</li> <li>Simply Wall St currently gives Veeva Systems a valuation score of 3 out of 6. The rest of this article will break down what that means using common valuation approaches, before finishing with a way to think about value that can be even more useful than any single model.</li> </ul> <p>Veeva Systems delivered -29.8% returns over the last year. See how this stacks up to the rest of the Healthcare Services industry.</p> <h3>Approach 1: Veeva Systems Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting future cash flows and discounting them back to today's value using a required rate of return.</p> <p>For Veeva Systems, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flows in $. The latest twelve month free cash flow (FCF) is about $1.39b. Analyst and extrapolated projections in the model run out to 2035, with forecast FCF in 2031 of about $2.43b, and discounted FCF figures each year that reflect the time value of money.</p> <p>Adding up all those discounted cash flows gives an estimated intrinsic value of about $293.79 per share. Against the current share price of around $168.25, the DCF output implies a 42.7% discount, which suggests the stock is currently priced below this model's estimate of fair value.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Veeva Systems is undervalued by 42.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b031edf7-d405-41d0-90b6-9277b4a7b051/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b031edf7-d405-41d0-90b6-9277b4a7b051/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA4"/><figcaption>VEEV Discounted Cash Flow as at May 2026</figcaption></figure> <p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Veeva Systems.</p> <h3>Approach 2: Veeva Systems Price vs Earnings</h3> <p>For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. Higher expected earnings growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually aligns with a lower, more conservative P/E.</p> <p>Veeva Systems currently trades on a P/E of 30.23x. This sits above the Healthcare Services industry average P/E of 28.37x, but below the peer group average of 33.50x. To go a step further, Simply Wall St estimates a “Fair Ratio” for Veeva Systems of 29.14x. This is the P/E that might be expected given factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics.</p> <p>This Fair Ratio can be more helpful than a simple comparison with industry or peers because it adjusts for company specific traits instead of assuming one size fits all. Comparing Veeva Systems actual P/E of 30.23x with the Fair Ratio of 29.14x suggests the stock is trading slightly above this tailored estimate.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b031edf7-d405-41d0-90b6-9277b4a7b051/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b031edf7-d405-41d0-90b6-9277b4a7b051/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA4"/><figcaption>NYSE:VEEV P/E Ratio as at May 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.</p> <h2>Upgrade Your Decision Making: Choose your Veeva Systems Narrative</h2> <p>Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple stories you choose about Veeva Systems that connect your view of its business, your estimates for future revenue, earnings and margins, and the fair value you think is reasonable.</p> <p>On Simply Wall St's Community page, Narratives let you pick or adjust a storyline that links what you believe about Veeva Systems, such as AI agents becoming central across Vault or CRM competition staying intense, to a structured forecast and a fair value number that sits beside the current share price to help you decide whether you see the stock as priced above or below your expectations.</p> <p>Because Narratives on the platform update automatically when fresh news, earnings or guidance arrive, they can reflect new information without you rebuilding a model from scratch, while still keeping your chosen assumptions in focus.</p> <p>For Veeva Systems, one investor might align with a higher fair value around US$380 on the assumption that AI agents, Development Cloud and data products scale strongly. Another might choose a lower fair value nearer US$233 if expectations are closer to modest revenue growth and flat margins. Seeing those side by side with the current price can make it clearer which story you are actually investing in.</p> <p>Do you think there's more to the story for Veeva Systems? Head over to our Community to see what others are saying!</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b031edf7-d405-41d0-90b6-9277b4a7b051/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b031edf7-d405-41d0-90b6-9277b4a7b051/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA4"/><figcaption>NYSE:VEEV 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

VEEV

LABU

SBIO

<p>Veeva Systems (VEEV) has seen a significant share price decline of 29.8% over the past year, currently priced at approximately $168.25. Despite a recent 7.9% gain in the past week, the stock has faced a 2.5% decline over the last month and a 23.3% drop year-to-date. A Discounted Cash Flow analysis suggests the stock is undervalued by 42.7%, estimating an intrinsic value of $293.79 per share. However, its P/E ratio of 30.23x is slightly above the fair ratio of 29.14x, indicating it may be overvalued compared to its tailored estimate.</p>

Simplywall

Veeva Systems -CL

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Is It Time To Reassess Veeva Systems (VEEV) After A 29.8% One-Year Share Price Fall